178 related articles for article (PubMed ID: 31094808)
21. Regulation of Pleiotrophin, Midkine, Receptor Protein Tyrosine Phosphatase β/ζ, and Their Intracellular Signaling Cascades in the Nucleus Accumbens During Opiate Administration.
García-Pérez D; Laorden ML; Milanés MV
Int J Neuropsychopharmacol; 2015 Jul; 19(1):. PubMed ID: 26164717
[TBL] [Abstract][Full Text] [Related]
22. Changes in the brain kappa-opioid receptor levels of rats in withdrawal from physical dependence upon butorphanol.
Fan LW; Tien LT; Tanaka S; Ma T; Chudapongse N; Sinchaisuk S; Rockhold RW; Ho IK
Neuroscience; 2003; 121(4):1063-74. PubMed ID: 14580956
[TBL] [Abstract][Full Text] [Related]
23. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression.
Schwarz JM; Hutchinson MR; Bilbo SD
J Neurosci; 2011 Dec; 31(49):17835-47. PubMed ID: 22159099
[TBL] [Abstract][Full Text] [Related]
24. Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence.
Wilson LL; Harris HM; Eans SO; Brice-Tutt AC; Cirino TJ; Stacy HM; Simons CA; León F; Sharma A; Boyer EW; Avery BA; McLaughlin JP; McCurdy CR
Drug Alcohol Depend; 2020 Nov; 216():108310. PubMed ID: 33017752
[TBL] [Abstract][Full Text] [Related]
25. Exposure to morphine-associated cues increases mu opioid receptor mRNA expression in the nucleus accumbens of Wistar Kyoto rats.
Dennis TS; Beck KD; Cominski TP; Bobzean SAM; Kuzhikandathil EV; Servatius RJ; Perrotti LI
Behav Brain Res; 2016 Oct; 313():208-213. PubMed ID: 27421830
[TBL] [Abstract][Full Text] [Related]
26. Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain.
Fan LW; Tanaka S; Tien LT; Ma T; Rockhold RW; Ho IK
Brain Res Bull; 2002 Jun; 58(2):149-60. PubMed ID: 12127012
[TBL] [Abstract][Full Text] [Related]
27. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
28. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
Sinchaisuk S; Ho IK; Rockhold RW
Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
[TBL] [Abstract][Full Text] [Related]
29. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
Crain SM; Shen KF
Brain Res; 2007 Sep; 1167():31-41. PubMed ID: 17692296
[TBL] [Abstract][Full Text] [Related]
30. Intravenous dezocine for postoperative pain: a double-blind, placebo-controlled comparison with morphine.
Pandit UA; Kothary SP; Pandit SK
J Clin Pharmacol; 1986 Apr; 26(4):275-80. PubMed ID: 2871049
[TBL] [Abstract][Full Text] [Related]
31. Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor.
Cook CD; Barrett AC; Roach EL; Bowman JR; Picker MJ
Psychopharmacology (Berl); 2000 Jul; 150(4):430-42. PubMed ID: 10958085
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine blocks withdrawal in morphine-dependent rat pups.
Stoller DC; Smith FL
Paediatr Anaesth; 2004 Aug; 14(8):642-9. PubMed ID: 15283822
[TBL] [Abstract][Full Text] [Related]
33. Assessment of dezocine for morphine-like subjective effects and miosis.
Jasinski DR; Preston KL
Clin Pharmacol Ther; 1985 Nov; 38(5):544-8. PubMed ID: 2865027
[TBL] [Abstract][Full Text] [Related]
34. An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity.
Morgan D; Cook CD; Smith MA; Picker MJ
Anesth Analg; 1999 Feb; 88(2):407-13. PubMed ID: 9972766
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine.
Jang S; Kim H; Kim D; Jeong MW; Ma T; Kim S; Ho IK; Oh S
Arch Pharm Res; 2006 Aug; 29(8):677-84. PubMed ID: 16964763
[TBL] [Abstract][Full Text] [Related]
36. Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats.
Petrie GN; Wills KL; Piscitelli F; Smoum R; Limebeer CL; Rock EM; Humphrey AE; Sheppard-Perkins M; Lichtman AH; Mechoulam R; Di Marzo V; Parker LA
Psychopharmacology (Berl); 2019 Sep; 236(9):2623-2633. PubMed ID: 30993360
[TBL] [Abstract][Full Text] [Related]
37. MiR-124-3p alleviates the dezocine tolerance against pain by regulating TRAF6 in a rat model.
Huo Y; Zhang K; Zhang T; Han Y; Hu Z
Neuroreport; 2021 Jan; 32(1):44-51. PubMed ID: 33165190
[TBL] [Abstract][Full Text] [Related]
38. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.
Noble F; Cox BM
Br J Pharmacol; 1996 Jan; 117(1):161-9. PubMed ID: 8825358
[TBL] [Abstract][Full Text] [Related]
39. The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats.
Kelsey JE; Verhaak AM; Schierberl KC
Behav Brain Res; 2015 Apr; 283():16-21. PubMed ID: 25591478
[TBL] [Abstract][Full Text] [Related]
40. Dezocine as a potent analgesic: overview of its pharmacological characterization.
Ye RR; Jiang S; Xu X; Lu Y; Wang YJ; Liu JG
Acta Pharmacol Sin; 2022 Jul; 43(7):1646-1657. PubMed ID: 34737418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
